Abstract #0434
GluCEST in the olfactory cortex as a marker of heightened clinical risk for schizophrenia
Ravi Prakash Reddy Nanga 1 , David R. Roalf 2 , Hari Hariharan 1 , Mark A. Elliott 1 , Karthik Prabhakaran 2 , Megan Quarmley 2 , Paul J. Moberg 2 , Ravinder Reddy 1 , and Bruce I. Turetsky 2
1
Radiology, University of Pennsylvania Health
Systems, Philadelphia, Pennsylvania, United States,
2
Psychiatry,
University of Pennsylvania, Philadelphia, Pennsylvania,
United States
In vivo measurement of glutamate neurotransmitter levels
in brain structures implicated in neuropsychiatry
disorders may provide insight into the role of these
structures play in the manifestation of symptoms and
potentially lead to improvements in therapy. Recent,
studies with methods based on glutamate chemical
exchange saturation transfer (GluCEST) in animal models
and humans suggest that GluCEST mapping may serve as a
biomarker of brain glutamate distribution, in vivo.
Here, we use GluCEST to map glutamate distributions,
within olfactory cortex, in healthy individuals (HC) and
individuals at clinical risk for developing
schizophrenia (CR).
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
